The Food and Drug Administration (FDA) is warning that an increased risk of death is possible with the use of duvelisib (Copiktra) compared with the monoclonal antibody ofatumumab in the treatment of chronic lymphocytic leukemia. Serious adverse effects also appear to be more likely with duvelisib use.Nurses should monitor for adverse effects and report them to the FDA's MedWatch program.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.NAJ.0000890208.43509.40 | DOI Listing |
Publication Analysis
Top Keywords
increased risk
8
risk death
8
adverse effects
8
death blood
4
blood cancer
4
cancer drug
4
drug food
4
food drug
4
drug administration
4
administration fda
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!